DUR: Educational Articles

The purpose of this educational intervention component of DUR is to improve the quality and cost-effectiveness of prescribing and dispensing practices for Medi-Cal recipients. Educational interventions include ongoing dissemination of information through the Medi-Cal provider bulletin process about clinically important, drug-specific therapy problems.

Disclaimer: These articles are the result of analyses carried out by the Global Medi-Cal DUR Program and are not official policies of the Department of Health Care Services (DHCS).

2021 Immunization Updates: COVID-19, Influenza, and Meningococcal Disease – September 2021

UPDATED: Drug Safety Communication: Voluntary Recall of Varenicline (Chantix) Due to Nitrosamine – September 2021

Drug Safety Communication: FDA Requests Removal of Pregnancy Contraindication for Statins – August 2021

Drug Safety Communication: Potential Increased Arrhythmia Risk from Lamotrigine – April 2021

Clinical Review: Recommendations for the Tapering of Benzodiazepines – March 2021

Clinical Review: Recommendations for the Management of Acute Dental Pain – January 2021

Drug Safety Communication: Stronger Warning Labels for Benzodiazepines – October 2020

2020 Immunization Updates: Vaccination during COVID-19, Flu, HepA, and Tdap – September 2020

Clinical Review: 2020 Standards of Care for Treatment of Type 2 Diabetes – August 2020

Clinical Guideline: Reproductive Health in Rheumatic and Musculoskeletal Diseases – May 2020

Improving Quality of Care: Update of Risks Associated with Use of Fluoroquinolones – April 2020

Drug Safety Communication: Withdrawal of All Ranitidine Products – April 2020

Drug Safety Communication: Mental Health Side Effects from Montelukast – March 2020

Improving the Quality of Care: Risks Associated with Use of Gabapentin – December 2019

Alert: New Global Guidelines for the Treatment of Asthma – October 2019

2019 Immunization Updates: Flu, HepA, HPV, Measles, CA School Requirements – September 2019

Clinical Review Update: Concomitant Anticholinergic and Antipsychotic Use – August 2019

Drug Safety Communication: Sleep Behavior Risks with Select Sleep Aids – June 2019

Drug Safety Communication: Risks with Sudden Discontinuation of Opioids – April 2019

Drug Safety Communication: Updated Adverse Effects from Fluoroquinolones – March 2019

Clinical Review Update: Morphine Equivalent Daily Dose – February 2019

Alert: New Naloxone Regulations Effective on January 1, 2019 – January 2019

2018 Immunization Updates: Flu, Tdap, HepB, Zoster, MMR, Adult Vaccines – September 2018

Alert: Mandatory Use of CURES 2.0 Begins October 2, 2018 – September 2018

ProDUR Update: Additive Toxicity Alert Now Focused Only On CNS Depressants – July 2018

Drug Safety Communication: Adverse Effects from Fluoroquinolone Antibiotics – July 2018

In the Pharmacy: Pharmacists Furnishing Nicotine Replacement Products – March 2018

Drug Safety Communication: New Age Limit for Opioid Cough and Cold Medicines – February 2018

Alert: Online Report to the Vaccine Adverse Event Reporting System (VAERS) – September 2017

2017 Immunization Updates: Influenza, HepA, Meningococcal, HPV, Adult Vaccines – September 2017

Clinical Review: Drug-Induced QT Interval Prolongation – August 2017

Drug Safety Communication: Risks of Codeine and Tramadol Use in Children – May 2017

Alert: Medi-Cal Expands Access to Adult Immunizations in Pharmacies – April 2017

Improving the Quality of Care: Overutilization of Proton Pump Inhibitors – April 2017

Improving the Quality of Care: Risks Associated with Use of Fluoroquinolones – February 2017

2016 Immunization Updates: Influenza, Meningococcal, Tdap, Hib, Rotavirus – September 2016

Clinical Review: The Treatment of Opioid Addiction with Buprenorphine – August 2016

Drug Safety Communication: New Safety Warnings Added to Prescription Opioids – April 2016

Clinical Review: Atypical Antipsychotics and Adverse Metabolic Effects – April 2016

Drug Safety Communication: Saxagliptin, Alogliptin and Risk of Heart Failure – April 2016

Alert: California Upgrades Prescription Drug Monitoring Program to CURES 2.0 – January 2016

Improving the Quality of Care: Updated Guidelines for Migraine Prevention – February 2013